| Cerus: An Unknown Gem That's Primed for a Boost Michael Shulman submits: Cerus (CERS) is unknown to most, but its technology and main product, the INTERCEPT System, is of importance to more people on the planet than Coca-Cola (KO), Intel (INTC) chips and perhaps Treasury bills.Intercept cleans blood platelets of almost everything, making the supply of platelets donor independent. Today Cerus and the Whittemore Peterson Institute published the results of joint research effort showing INTERCEPT inactivated the XMRV virus. XMRV has been anecdotally linked with Chronic Fatigue Syndrome (CFS). For this reason, the UK, Canada, New Zealand and Australia have banned patients with CFS from giving blood. These results proves the widespread applicability of INTERCEPT to many known and unknown pathogens. Complete results may be presented at the American Association of Blood Banks conference in October.Complete Story » seekingalpha.com |
eyeforpharma: Sales Force Effectiveness - Video Several Key Themes About Change and Customer-Centricity Emerged at This Year’s eyeforpharma’s SFE 2010 Conference in Barcelona, April 27-29th. feedproxy.google.com |
Protecting your skin from sun damage - Video An Industry-First Campaign to Educate Tour Players & Fans on Prevention and Treatment of Sun Damage Including Fraxel’s re:store Laser Technology feedproxy.google.com |
Big Pharma: Why In-Licensing Is Not the Cure Jason Chew submits: Historically, the Big Pharma business model has been that of a fully integrated pharmaceutical company, complete with basic research and development, clinical trials, sales and marketing, focused on the development of blockbuster drugs. This model has recently been roundly criticized.A research article issued in January from Morgan Stanley (MS) titled "Pharmaceuticals: Exit Research and Create Value" created a stir when it called for Big Pharma to toss out all small molecule research. A group of MDs, PhDs, MBAs, and CFAs calculated that reinvesting internal research to in-licensing would result in a three-fold increase in returns. This process, they said, would even triple the number of new drugs reaching the market each year. Research and Development, Morgan Stanley said, should be replaced by Search and Development. The core competency of Big Phama should shift from in-house research to late stage development and commercialization.Complete Story » seekingalpha.com |
Cord Blood America Management Team to Appear on National VoiceAmerica Radio Network [PR Newswire] - Cord Blood America, Inc. , the umbilical cord blood stem cell preservation company focused on bringing the life-saving potential of stem cells to families nationwide and internationally, is pleased to announce that Chairman, CEO and co-founder Matthew Schissler and Dr. us.rd.yahoo.com |